The article below from Proactive Investors is now being...

The article below from Proactive Investors is now being circulated to their members and judging by todays aggresive buying, Brendan Fleiter's appointment has given new confidense to investors.

Consegna Group welcomes Brendan Fleiter to the Board
Wednesday, November 16, 2011 by Proactive Investors Consegna Group (ASX: CGP) has appointed Brendan Fleiter to the Board as a non-executive director.

Fleiter has extensive commercial experience having practiced as a commercial lawyer for many years before spending 13 years with the Crazy John’s group as a non-executive director and later chief executive officer.

He was a non-executive director of the ASX-listed People Telecom for seven years before its merger with M2 Telecom and is currently a non-executive director of Australia Post. Fleiter is also a director of several not for profit organisations.

Managing director Fabio Pannuti said Fleiter’s appointment is timely given the new stages of commercialisation Consegna is entering into.

Late last month the company announced it had delivered a milestone for the company's Vibrovein™ Technology, by demonstrating a proof of concept.

Vibrovein™ is a small vibrating device that attaches to the barrel of any syringe to reduce penetration resistance and thereby reduce pain and tissue distortion and increase needle efficiency and patient comfort.

The impact from Vibrovein™ being able to produce up to a 60% reduction in the force required to cause a hypodermic needle to penetrate a membrane of human skin has the potential to deliver some significant licensing and patent opportunities.

Consegna has also received notices of acceptance from the Australian Patents Office of two patent applications in relation to the company's BreatheAssist™ product.

BreatheAssist™ is a new multi-functional nasal dilation technology.

The Australian patent acceptance follows the prior granting of patents in Japan, China and New Zealand, and corresponding patents in the U.S. with patents pending in Europe.

The company said the latest patents provided even greater confidence about the commercial potential for BreatheAssist™.


DYOR

regards

Eyeknow